Skip to content
Peptigraph home
Shop Peptides50% off*

Retatrutide Benefits: Claims vs What Studies Show

Benefits people claim for Retatrutide, set against what published studies measured, and where no study exists.

Medical review pendingGLP-1 / GIP / glucagon triple agonistUpdated
Strongest evidence
Human RCT
Human / animal studies
11 / 2
in our evidence file (PubMed search, 2 Oct 2026)
FDA status
Not approved
Investigational · phase 3

Claimed benefits and what studies show

Each row is an area where people claim a benefit, with the strongest study we summarise behind it. Animal and cell results are labelled and are not human results. User reports are not counted as evidence here.

Retatrutide claimed benefits and the studies behind them
ClaimBest evidenceStudies (human / animal)What was measuredPage
Weight lossHuman RCT evidence, 4 of 49 / 2Body weight; Body weight at week 80 (primary); Body weight at week 40Evidence for weight loss
DiabetesHuman RCT evidence, 4 of 44 / 1Body weight at week 80 (primary); Glycaemic control; HbA1c at week 40 (primary)Evidence for diabetes
Heart healthHuman RCT evidence, 4 of 42 / 0Atherogenic lipoproteins; Inflammatory markers; ANGPTL3/8 and lipidsEvidence for heart health
MetabolismHuman RCT evidence, 4 of 44 / 0HbA1c at week 40 (primary); Hunger and disinhibition; Link to weight, abdominal fat and insulin sensitivityEvidence for metabolism
Liver healthHuman RCT evidence, 4 of 41 / 1Liver fat at 24 weeks (primary); Normal liver fat (<5%); Link to weight, abdominal fat and insulin sensitivityEvidence for liver health
Joint painHuman RCT evidence, 4 of 41 / 0Knee osteoarthritis pain (WOMAC)Evidence for joint pain
InflammationHuman RCT evidence, 4 of 41 / 0Inflammatory markersEvidence for inflammation
Muscle growthHuman RCT evidence, 4 of 41 / 0Lean mass share of weight lossEvidence for muscle growth

Strongest study per claim: Weight loss, The New England journal of medicine 2026, PMID 42814954; Diabetes, Lancet 2026, PMID 42810372; Heart health, Diabetes, obesity & metabolism 2026, PMID 42608321.

What the studies measured

Retatrutide outcomes in published studies
OutcomeResultStudy typeSource
Body weightMean body weight change was -25.0% with 12 mg, -23.7% with 9 mg and -17.6% with 4 mg, versus -3.9% with placebo.Human RCTn = 2339The New England journal of medicine 2026, PMID 42814954
Knee osteoarthritis pain (WOMAC)In people with knee osteoarthritis the WOMAC pain score changed by -3.2, -3.5 and -3.6 across the retatrutide groups versus -1.9 with placebo (hybrid estimand).Human RCTn = 2339The New England journal of medicine 2026, PMID 42814954
Apnea-hypopnea index (sleep apnea)In people with obstructive sleep apnea, events per hour changed by -22.8, -34.3 and -32.1 across the retatrutide groups versus -9.6 with placebo (ITT estimand).Human RCTn = 2339The New England journal of medicine 2026, PMID 42814954
Body weight at week 80 (primary)At week 80 body weight changed by -18·8% with 12 mg, -16·8% with 9 mg and -11·9% with 4 mg, versus -5·1% with placebo.Human RCTn = 1152Lancet 2026, PMID 42810372
Glycaemic controlRetatrutide was associated with improved glycaemic control in obesity with type 2 diabetes (no HbA1c figure in the abstract).Human RCTn = 1152Lancet 2026, PMID 42810372
HbA1c at week 40 (primary)HbA1c changed by -1·94% with 12 mg, -1·86% with 9 mg and -1·69% with 4 mg, versus -0·81% with placebo.Human RCTn = 537Lancet 2026, PMID 42250575
Body weight at week 40Body weight changed by -15·3% with 12 mg, -13·9% with 9 mg and -11·5% with 4 mg, versus -2·6% with placebo.Human RCTn = 537Lancet 2026, PMID 42250575
Atherogenic lipoproteinsNon-HDL cholesterol fell by up to -21.0% (Study 1) and -26.9% (Study 2); apolipoprotein B by -21.4% and -24.2%.Human controlled trialDiabetes, obesity & metabolism 2026, PMID 42608321
Inflammatory markersHigh-sensitivity C-reactive protein fell by -54.8% and interleukin-6 by -29.6% in Study 2 but not Study 1.Human controlled trialDiabetes, obesity & metabolism 2026, PMID 42608321
Total fat mass (DXA)Total fat mass fell by 26·1% with 8 mg (pooled), 23·2% with 12 mg and 15·2% with 4 mg (pooled), versus 2·6% with dulaglutide and 4·5% with placebo.Human RCTn = 189The lancet. Diabetes & endocrinology 2025, PMID 40609566
Lean mass share of weight lossThe authors report lean mass loss as a proportion of weight loss was similar to other obesity treatments.Human RCTn = 189The lancet. Diabetes & endocrinology 2025, PMID 40609566
Hunger and disinhibitionPerceived hunger and tendency to overeat were reduced with higher retatrutide doses versus placebo.Human RCTn = 275Diabetes, obesity & metabolism 2025, PMID 40916752
ANGPTL3/8 and lipidsRetatrutide-induced reductions in the ANGPTL3/8 complex paralleled reductions in triglycerides and LDL-C.Human controlled trialDiabetes, obesity & metabolism 2025, PMID 40726454
Liver fat at 24 weeks (primary)Liver fat changed by -82.4% with 12 mg and -42.9% with 1 mg, versus +0.3% with placebo at 24 weeks.Human RCTn = 98Nature medicine 2024, PMID 38858523
Normal liver fat (<5%)Normal liver fat was reached by 86% on 12 mg and 27% on 1 mg versus 0% on placebo.Human RCTn = 98Nature medicine 2024, PMID 38858523
Link to weight, abdominal fat and insulin sensitivityLiver fat reductions were significantly related to changes in body weight, abdominal fat and metabolic measures (an association, not a separate abdominal-fat result).Human RCTn = 98Nature medicine 2024, PMID 38858523
Body weight at 24 weeks (primary)At 24 weeks body weight changed by -17.5% with 12 mg and -7.2% with 1 mg, versus -1.6% with placebo.Human RCTn = 338The New England journal of medicine 2023, PMID 37366315
Body weight at 48 weeksAt 48 weeks body weight changed by -24.2% with 12 mg and -8.7% with 1 mg, versus -2.1% with placebo.Human RCTn = 338The New England journal of medicine 2023, PMID 37366315
Proportion reaching 5%, 10%, 15% weight lossWith 12 mg, 100%, 93% and 83% reached a 5%, 10% and 15% weight reduction at 48 weeks, versus 27%, 9% and 2% with placebo.Human RCTn = 338The New England journal of medicine 2023, PMID 37366315
HbA1c at 24 weeks (primary)HbA1c changed by -2·02% with 12 mg escalation, versus -0·01% with placebo and -1·41% with 1·5 mg dulaglutide.Human RCTn = 281Lancet 2023, PMID 37385280

Showing the first 20 of 33 rows, strongest sources first.

Not shown in any study we cite. Searches behind this page: PubMed search on 2 Oct 2026 for “retatrutide[tiab] OR LY3437943[tiab]”: 197 results. PubMed search on 2 Oct 2026 for “(retatrutide[tiab] OR LY3437943[tiab]) AND (randomized[tiab] OR trial[tiab] OR phase[tiab])”: 96 results. PubMed search on 2 Oct 2026 for “(retatrutide[tiab] OR LY3437943[tiab]) AND (obesity[tiab] OR diabetes[tiab] OR liver[tiab] OR osteoarthritis[tiab]) AND "Clinical Trial"[pt]”: 8 results. PubMed search on 2 Oct 2026 for “(retatrutide[tiab] OR LY3437943[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab])”: 9 results.

Claim: it causes large weight loss

Adults with obesity but no diabetes lost a mean of 25.0% of body weight on the top dose in the phase 3 trial, against 3.9% on placebo.[2]

In the phase 2 obesity trial, the mean weight change at 48 weeks was -24.2% in the 12 mg group, compared with -2.1% on placebo.[1]

A network meta-analysis of weight-loss drugs found retatrutide carried the highest adverse-event risk among those compared.[17]

Claim: it lowers blood sugar

Adults with type 2 diabetes on diet and exercise alone saw HbA1c fall 1.94% on the top retatrutide dose against 0.81% on placebo in that monotherapy trial.[5]

The phase 2 diabetes trial said retatrutide reduced HbA1c more than 1.5 mg dulaglutide in its 8 mg slow-escalation and 12 mg groups.[11]

Claim: it eases knee pain and protects the heart

In the knee osteoarthritis subgroup of the phase 3 obesity trial, the largest pain-score fall on retatrutide was 3.6 points against 1.9 on placebo (hybrid estimand).[2]

For the heart, the evidence found is blood-pressure and lipid measurements pooled across trials, not heart events: systolic pressure fell by 6.79 mmHg on average.[18]

Claim: it clears fatty liver and calms inflammation

Liver fat fell by 82.4% on 12 mg and 81.4% on 8 mg in the 24-week fatty-liver substudy, while placebo moved by +0.3%.[10]

High-sensitivity C-reactive protein fell by 54.8% in the obesity study without diabetes, but the diabetes study did not show the same fall.[6]

Claim: it builds muscle and speeds metabolism

The body-composition substudy concluded that the share of lean mass lost within the weight lost was similar to other obesity treatments, which is lean-mass data and not muscle gain.[7]

Appetite, not metabolic rate, is what the diabetes questionnaire study measured: perceived hunger and the tendency to overeat were reduced at higher doses.[8]

How thin the evidence is for fat mass and lean mass

A PubMed search of retatrutide with fat mass, body fat and lean mass terms (2026-10-02) found 7 human-only papers and 2 under the animal filter; 1 carried a randomized-trial tag.

Calculated from pubmed query (retatrutide[tiab] OR LY3437943[tiab]) AND ("fat loss"[tiab] OR "fat mass"[tiab] OR "body fat"[tiab] OR "body composition"[tiab] OR "lean mass"[tiab] OR "lean body mass"[tiab] OR "fat-free mass"[tiab]); date 2026-10-02; human only count 7; animal filter count 2; randomized filter count 1. Formula: counts as recorded in the goals.json ledger (PubMed [tiab] query with the human-only, animal and RCT filters shown)

How thin the evidence is for metabolic rate

A PubMed search of retatrutide with metabolism or energy-expenditure terms (2026-10-02) found 6 human-only papers and 4 under the animal filter; 1 carried a randomized-trial tag.

Calculated from pubmed query (retatrutide[tiab] OR LY3437943[tiab]) AND ("energy expenditure"[tiab] OR "metabolic rate"[tiab] OR "metabolic syndrome"[tiab] OR "insulin sensitivity"[tiab] OR "lipid metabolism"[tiab] OR "glucose metabolism"[tiab] OR "fat oxidation"[tiab] OR lipolysis[tiab] OR thermogen*[tiab] OR "metabolic health"[tiab]); date 2026-10-02; human only count 6; animal filter count 4; randomized filter count 1. Formula: counts as recorded in the goals.json ledger (PubMed [tiab] query with the human-only, animal and RCT filters shown)

How thin the evidence is for blood pressure

A PubMed search of retatrutide with blood pressure terms (2026-10-02) found 9 human-only papers and 0 under the animal filter; 0 carried a randomized-trial tag.

Calculated from pubmed query (retatrutide[tiab] OR LY3437943[tiab]) AND ("blood pressure"[tiab] OR hypertension[tiab] OR hypertensive[tiab] OR antihypertensive[tiab]); date 2026-10-02; human only count 9; animal filter count 0; randomized filter count 0. Formula: counts as recorded in the goals.json ledger (PubMed [tiab] query with the human-only, animal and RCT filters shown)

More on Retatrutide

DosageSide effectsResultsHow it works

Common questions

Is Retatrutide proven to work?

The strongest study we summarise for Retatrutide is human rct evidence, among 16 studies. A trial result is not an approval; see the legal status.

What does retatrutide do?

In the phase 3 obesity trial, retatrutide at 4 mg, 9 mg or 12 mg once weekly lowered mean body weight by 17.6%, 23.7% and 25.0% against 3.9% on placebo.[2]

What are the benefits of retatrutide for people with obstructive sleep apnea?

In the phase 3 obesity trial's sleep apnea subgroup, apnea-hypopnea events per hour fell by 22.9 on the lowest dose, 34.3 on the middle dose and 31.7 on the top dose for the hybrid estimand, against 9.9 on placebo.[2]

More on Retatrutide

DosageDoses used in published trials, the titration pattern and a units chart.CalculatorVial, water and dose to syringe units.Side effectsWhat labels and studies report, and what is unknown.ResultsStudy outcomes and when they were measured.PricePrice per mg and per week from dated listings. No vendor links.How it worksTarget, mechanism and how long it acts, from the label or studies.

Sources

  1. 1Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial (Jastreboff AM et al.)New England Journal of Medicine · 2023PMID 37366315Accessed 2 Oct 2026
  2. 2Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity (TRIUMPH-1; Jastreboff AM et al.)New England Journal of Medicine · 2026PMID 42814954Accessed 2 Oct 2026
  3. 3A Phase 2 Study of Once-Weekly LY3437943 Compared With Placebo in Participants Who Have Obesity or Are Overweight With Weight-Related Comorbidities (NCT04881760; arms and posted results)ClinicalTrials.gov (U.S. National Library of Medicine) · 2021clinicaltrials.govAccessed 2 Oct 2026
  4. 4Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial.Lancet (London, England) · 2026PMID 42810372Accessed 2 Oct 2026
  5. 5Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial.Lancet (London, England) · 2026PMID 42250575Accessed 2 Oct 2026
  6. 6Retatrutide-Associated Improvements in Cardiovascular Risk Biomarkers in Adults With Obesity With or Without Type 2 Diabetes.Diabetes, obesity & metabolism · 2026PMID 42608321Accessed 2 Oct 2026
  7. 7Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial.The lancet. Diabetes & endocrinology · 2025PMID 40609566Accessed 2 Oct 2026
  8. 8Appetite, eating attitudes, and eating behaviours during treatment with retatrutide in adults with type 2 diabetes: Results of a phase 2 study.Diabetes, obesity & metabolism · 2025PMID 40916752Accessed 2 Oct 2026
  9. 9Decreases in circulating ANGPTL3/8 concentrations following retatrutide treatment parallel reductions in serum lipids.Diabetes, obesity & metabolism · 2025PMID 40726454Accessed 2 Oct 2026
  10. 10Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial.Nature medicine · 2024PMID 38858523Accessed 2 Oct 2026
  11. 11Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.Lancet (London, England) · 2023PMID 37385280Accessed 2 Oct 2026
  12. 12PubMed search: retatrutide[tiab] OR LY3437943[tiab] (197 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  13. 13PubMed search: (retatrutide[tiab] OR LY3437943[tiab]) AND (randomized[tiab] OR trial[tiab] OR phase[tiab]) (96 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  14. 14PubMed search: (retatrutide[tiab] OR LY3437943[tiab]) AND (obesity[tiab] OR diabetes[tiab] OR liver[tiab] OR osteoarthritis[tiab]) AND "Clinical Trial"[pt] (8 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  15. 15PubMed search: (retatrutide[tiab] OR LY3437943[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (9 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  16. 16PubMed search: (SYNCHRONIZE[tiab] OR TRIUMPH[tiab] OR GLORY[tiab] OR DREAMS[tiab]) AND (survodutide[tiab] OR retatrutide[tiab] OR mazdutide[tiab]) (27 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  17. 17Efficacy and Safety of GLP-1 Receptor Agonists, Dual Agonists, and Retatrutide for Weight Loss in Adults With Overweight or Obesity: A Bayesian NMA.Obesity (Silver Spring, Md.) · 2025PMID 40685589Accessed 2 Oct 2026
  18. 18Effect of Retatrutide, a Novel Triple Receptor Agonist, on Blood Pressure and Lipid Levels: A Systematic Review and Meta-analysis of Randomized Controlled Trials.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2026PMID 42371360Accessed 2 Oct 2026

Found an error? Report a correction.